Principal Investigator

Kendrith Martin
Rowland
Awardee Organization

Carle Foundation
United States

Fiscal Year
2023
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Carle Cancer Center NCI Community Oncology Research Program (NCORP)

Carle Cancer Center in Urbana, Illinois, a current NCI Community Oncology Research Program (NCORP), is applying for renewed funding to continue its commitment to provide cancer prevention, control, screening, and care delivery research in the community setting. Joining in our efforts are affiliate institutions, Rush-Copley Medical Center in Aurora, Illinois and St. Vincent Anderson in Anderson, Indiana. Together, the NCORP affiliate institutions' objectives are to engage institutions and communities in the participation of research to advance all aspects of cancer care. The goal is to optimize the personal and institutional advances in health care through research that becomes readily transferable across other health care systems and populations for the benefit of all. The Carle NCORP is devoted to engage all members and communities to be represented in clinical and translational research. Over the next six years, the Carle NCORP will continue to recruit, train, and mentor any population or health system in the region to similarly participate in clinical research. Carle's strength is its highly integrated health care system, from top to bottom (organizationally and electronically), comprised of 928 primary care and specialty providers, all invested in a research culture. The Carle NCORP's three main strengths are cancer control, prevention, and care delivery research, novel imaging, and capabilities to acquire bio-specimens. Attributes in place to ensure a successful NCORP include: • Over 35 years of community research oncology experience • Multi-disciplinary and multi-institutional integration • Significant rural and diverse population in eastern Illinois and portions of Indiana • High accrual particularly with cancer control, prevention, and care delivery trials • Cross discipline research initiatives at Carle Foundation Hospital, Rush Copley, and St. Vincent Anderson • Stephens Family Clinical Research Institute infrastructure and support • Institutional support for the underserved and for the research program as a whole • Affiliation with academic centers • Initiatives for imaging, bio-specimen, electronic data mining • High quality data • Strong regulatory processes

Publications

  • Argiris A, Miao J, Cristea MC, Chen AM, Sands JM, Decker RH, Gettinger SN, Daly ME, Faller BA, Albain KS, Yanagihara RH, Garland LL, Byers LA, Wang D, Koczywas M, Redman MW, Kelly K, Gandara DR. A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811). Clinical lung cancer. 2021 Jul;22(4):313-323.e1. Epub 2021 Feb 19. PMID: 33745865
  • Ahmad SA, Duong M, Sohal DPS, Gandhi NS, Beg MS, Wang-Gillam A, Wade JL 3rd, Chiorean EG, Guthrie KA, Lowy AM, Philip PA, Hochster HS. Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma. Annals of surgery. 2020 Sep 1;272(3):481-486. PMID: 32740235
  • Slade AN, Stanic S. The impact of RTOG 0614 and RTOG 0933 trials in routine clinical practice: The US Survey of Utilization of Memantine and IMRT planning for hippocampus sparing in patients receiving whole brain radiotherapy for brain metastases. Contemporary clinical trials. 2016 Mar;47:74-7. Epub 2015 Dec 21. PMID: 26718093
  • Cathcart-Rake E, Novotny P, Leon-Ferre R, Le-Rademacher J, Storrick EM, Adjei AA, Terstriep S, Glaser R, Giuliano A, Mitchell WR, Page S, Austin C, Deming RL, Ferreira MA, Lafky JM, Birrell SN, Loprinzi CL. A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2021 Jan;29(1):387-396. Epub 2020 May 6. PMID: 32372176
  • Miller RC, Petereit DG, Sloan JA, Liu H, Martenson JA, Bearden JD 3rd, Sapiente R, Seeger GR, Mowat RB, Liem B, Iott MJ, Loprinzi CL, Alliance for Clinical Trials in Oncology. N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy. International journal of radiation oncology, biology, physics. 2016 Jul 15;95(4):1168-74. Epub 2016 Apr 23. PMID: 27354129
  • Chiorean EG, Guthrie KA, Philip PA, Swisher EM, Jalikis F, Pishvaian MJ, Berlin J, Noel MS, Suga JM, Garrido-Laguna I, Cardin DB, Radke MR, Duong M, Bellasea S, Lowy AM, Hochster HS. Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Dec 1;27(23):6314-6322. Epub 2021 Sep 27. PMID: 34580114
  • Jatoi A, Steen PD, Atherton PJ, Moore DF, Rowland KM, Le-Lindqwister NA, Adonizio CS, Jaslowski AJ, Sloan J, Loprinzi C. A double-blind, placebo-controlled randomized trial of creatine for the cancer anorexia/weight loss syndrome (N02C4): an Alliance trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Aug 1;28(8):1957-1963. PMID: 28475678
  • Parikh K, Mandrekar SJ, Allen-Ziegler K, Esplin B, Tan AD, Marchello B, Adjei AA, Molina JR. A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance). The oncologist. 2020 Jun;25(6):523-531. Epub 2019 Dec 24. PMID: 31872928
  • Stein MN, Chen YH, Carducci MA, Hudes GR, Lerma PM, Tan WW, Dalune R, Rowland KM, Kuzel TM, DiPaola RS. Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805). American journal of clinical oncology. 2019 Apr;42(4):375-381. PMID: 30789412
  • Zhao Y, Foster NR, Meyers JP, Thomas SP, Northfelt DW, Rowland KM Jr, Mattar BI, Johnson DB, Molina JR, Mandrekar SJ, Schild SE, Bearden JD 3rd, Aubry MC, Adjei AA. A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Jan;10(1):172-80. PMID: 25247339
  • Halfdanarson TR, Foster NR, Kim GP, Haddock MG, Dakhil SR, Behrens RJ, Alberts SR. N064A (Alliance): Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Adenocarcinoma. The oncologist. 2022 Jul 5;27(7):534-e546. PMID: 35285484
  • Aggarwal C, Redman MW, Lara PN Jr, Borghaei H, Hoffman P, Bradley JD, Newman AJ 3rd, Feldman MJ, Minichiello K, Miao J, Mack PC, Papadimitrakopoulou VA, Herbst RS, Kelly K, Gandara DR. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Oct;14(10):1847-1852. Epub 2019 Jun 11. PMID: 31195180
  • Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR Jr, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA. 2017 Jan 3;317(1):48-58. PMID: 28030702
  • Galanis E, Anderson SK, Twohy EL, Carrero XW, Dixon JG, Tran DD, Jeyapalan SA, Anderson DM, Kaufmann TJ, Feathers RW, Giannini C, Buckner JC, Anastasiadis PZ, Schiff D. A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. Cancer. 2019 Nov 1;125(21):3790-3800. Epub 2019 Jul 10. PMID: 31290996
  • Jaeckle KA, Anderson SK, Twohy EL, Dixon JG, Giannini C, Jenkins R, Egorin MJ, Sarkaria JN, Brown PD, Flynn PJ, Schwerkoske J, Buckner JC, Galanis E. Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). Journal of neuro-oncology. 2019 Jul;143(3):573-581. Epub 2019 May 22. PMID: 31119479
  • Wagner LI, Pugh SL, Small W Jr, Kirshner J, Sidhu K, Bury MJ, DeNittis AS, Alpert TE, Tran B, Bloom BF, Mai J, Yeh A, Sarma K, Becker M, James J, Bruner DW. Screening for depression in cancer patients receiving radiotherapy: Feasibility and identification of effective tools in the NRG Oncology RTOG 0841 trial. Cancer. 2017 Feb 1;123(3):485-493. Epub 2016 Nov 10. PMID: 27861753